Roche nabs breakthrough tag for TIGIT cancer immunotherapy
pharmaphorum
JANUARY 5, 2021
TIGIT is very much among the front runners however, and Roche is being closely pursued by other drug developers including Merck & Co with MK-7684 and Gilead/Arcus, which are also in mid-stage testing, as well as iTeos Therapeutics and Mereo BioPharma.
52 
Let's personalize your content